Lévy Y., Lacabaratz C., Ellefsen-Lavoie K., Stöhr W., Lelièvre J.D., Bart P.A., Launay O., Weber J., Salzberger B., Wiedemann A., Surenaud M., Koelle D.M., Wolf H., Wagner R., Rieux V., Montefiori D.C., Yates N.L., Tomaras G.D., Gottardo R., Mayer B., Ding S., Thiébaut R., McCormack S., Chêne G., Pantaleo G.

Jun 26, 2020 | Publications

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

Moodie Z., Walsh S.R., Laher F., Maganga L., Herce M.E., Naidoo S., Hosseinipour M.C., Innes C., Bekker L.G., Grunenberg N., Mann P., Yu C., deCamp A.C., Miner M.D., Yates N.L., Heptinstall J., Mkhize N.N., Dintwe O., Frahm N., Cohen KW., Allen M., Hutter J., Wagner R., Pantaleo G., McElrath M.J., Tomaras G.D., Morris L., Montefiori D.C., Andersen-Nissen E., Gray G.E., Gilbert P.B., Kublin J.G.; NIAID HVTN 100 and HVTN 111 trial teams.

May 22, 2020 | Publications

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials